C-Myc suppresses microRNA-29b to promote tumor aggressiveness and poor outcomes in non-small cell lung cancer by targeting FHIT

D. W. Wu, N. Y. Hsu, Y. C. Wang, M. C. Lee, Y. W. Cheng, C. Y. Chen, H. Lee

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

The dual role of the microRNA-29 (miR-29) family in tumor progression and metastasis in solid tumors has been reported. Evidence for the role of miR-29 in tumor malignancy and its prognostic value in overall survival (OS) and relapse-free survival (RFS) in non-small cell lung cancer (NSCLC) remains conflicting. Mechanistic studies presented herein demonstrated that c-Myc suppressed the expression of miR-29b, promoting soft agar growth and invasion capability in lung cancer cells. Interestingly, the decrease in the expression of miR-29b by c-Myc is responsible for soft agar growth and invasiveness mediated by FHIT loss due to promoter methylation. Among patients, low expression of miR-29b and FHIT was more common in tumors with high c-Myc expression than in tumors with low c-Myc expression. Kaplan-Meier and Cox regression analysis showed that tumors with high c-Myc, low miR-29b and low FHIT expression had shorter OS and RFS periods than their counterparts. In conclusion, the decrease in the expression of miR-29b by c-Myc may be responsible for FHIT loss-mediated tumor aggressiveness and for poor outcome in NSCLC. Therefore, we suggest that restoration of the miR-29b expression using the c-Myc inhibitor might be helpful in suppressing tumor aggressiveness mediated by FHIT loss and consequently improving outcomes in NSCLC patients with tumors with low expression of FHIT.

Original languageEnglish
Pages (from-to)2072-2082
Number of pages11
JournalOncogene
Volume34
Issue number16
DOIs
Publication statusPublished - Jun 9 2014

Fingerprint

MicroRNAs
Non-Small Cell Lung Carcinoma
Neoplasms
Survival
Agar
Recurrence
Growth
Methylation
Lung Neoplasms
Regression Analysis
Neoplasm Metastasis

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics
  • Medicine(all)

Cite this

Wu, D. W., Hsu, N. Y., Wang, Y. C., Lee, M. C., Cheng, Y. W., Chen, C. Y., & Lee, H. (2014). C-Myc suppresses microRNA-29b to promote tumor aggressiveness and poor outcomes in non-small cell lung cancer by targeting FHIT. Oncogene, 34(16), 2072-2082. https://doi.org/10.1038/onc.2014.152

C-Myc suppresses microRNA-29b to promote tumor aggressiveness and poor outcomes in non-small cell lung cancer by targeting FHIT. / Wu, D. W.; Hsu, N. Y.; Wang, Y. C.; Lee, M. C.; Cheng, Y. W.; Chen, C. Y.; Lee, H.

In: Oncogene, Vol. 34, No. 16, 09.06.2014, p. 2072-2082.

Research output: Contribution to journalArticle

Wu, D. W. ; Hsu, N. Y. ; Wang, Y. C. ; Lee, M. C. ; Cheng, Y. W. ; Chen, C. Y. ; Lee, H. / C-Myc suppresses microRNA-29b to promote tumor aggressiveness and poor outcomes in non-small cell lung cancer by targeting FHIT. In: Oncogene. 2014 ; Vol. 34, No. 16. pp. 2072-2082.
@article{c38061f7ac8e46bb913f39bf1bfd2615,
title = "C-Myc suppresses microRNA-29b to promote tumor aggressiveness and poor outcomes in non-small cell lung cancer by targeting FHIT",
abstract = "The dual role of the microRNA-29 (miR-29) family in tumor progression and metastasis in solid tumors has been reported. Evidence for the role of miR-29 in tumor malignancy and its prognostic value in overall survival (OS) and relapse-free survival (RFS) in non-small cell lung cancer (NSCLC) remains conflicting. Mechanistic studies presented herein demonstrated that c-Myc suppressed the expression of miR-29b, promoting soft agar growth and invasion capability in lung cancer cells. Interestingly, the decrease in the expression of miR-29b by c-Myc is responsible for soft agar growth and invasiveness mediated by FHIT loss due to promoter methylation. Among patients, low expression of miR-29b and FHIT was more common in tumors with high c-Myc expression than in tumors with low c-Myc expression. Kaplan-Meier and Cox regression analysis showed that tumors with high c-Myc, low miR-29b and low FHIT expression had shorter OS and RFS periods than their counterparts. In conclusion, the decrease in the expression of miR-29b by c-Myc may be responsible for FHIT loss-mediated tumor aggressiveness and for poor outcome in NSCLC. Therefore, we suggest that restoration of the miR-29b expression using the c-Myc inhibitor might be helpful in suppressing tumor aggressiveness mediated by FHIT loss and consequently improving outcomes in NSCLC patients with tumors with low expression of FHIT.",
author = "Wu, {D. W.} and Hsu, {N. Y.} and Wang, {Y. C.} and Lee, {M. C.} and Cheng, {Y. W.} and Chen, {C. Y.} and H. Lee",
year = "2014",
month = "6",
day = "9",
doi = "10.1038/onc.2014.152",
language = "English",
volume = "34",
pages = "2072--2082",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "16",

}

TY - JOUR

T1 - C-Myc suppresses microRNA-29b to promote tumor aggressiveness and poor outcomes in non-small cell lung cancer by targeting FHIT

AU - Wu, D. W.

AU - Hsu, N. Y.

AU - Wang, Y. C.

AU - Lee, M. C.

AU - Cheng, Y. W.

AU - Chen, C. Y.

AU - Lee, H.

PY - 2014/6/9

Y1 - 2014/6/9

N2 - The dual role of the microRNA-29 (miR-29) family in tumor progression and metastasis in solid tumors has been reported. Evidence for the role of miR-29 in tumor malignancy and its prognostic value in overall survival (OS) and relapse-free survival (RFS) in non-small cell lung cancer (NSCLC) remains conflicting. Mechanistic studies presented herein demonstrated that c-Myc suppressed the expression of miR-29b, promoting soft agar growth and invasion capability in lung cancer cells. Interestingly, the decrease in the expression of miR-29b by c-Myc is responsible for soft agar growth and invasiveness mediated by FHIT loss due to promoter methylation. Among patients, low expression of miR-29b and FHIT was more common in tumors with high c-Myc expression than in tumors with low c-Myc expression. Kaplan-Meier and Cox regression analysis showed that tumors with high c-Myc, low miR-29b and low FHIT expression had shorter OS and RFS periods than their counterparts. In conclusion, the decrease in the expression of miR-29b by c-Myc may be responsible for FHIT loss-mediated tumor aggressiveness and for poor outcome in NSCLC. Therefore, we suggest that restoration of the miR-29b expression using the c-Myc inhibitor might be helpful in suppressing tumor aggressiveness mediated by FHIT loss and consequently improving outcomes in NSCLC patients with tumors with low expression of FHIT.

AB - The dual role of the microRNA-29 (miR-29) family in tumor progression and metastasis in solid tumors has been reported. Evidence for the role of miR-29 in tumor malignancy and its prognostic value in overall survival (OS) and relapse-free survival (RFS) in non-small cell lung cancer (NSCLC) remains conflicting. Mechanistic studies presented herein demonstrated that c-Myc suppressed the expression of miR-29b, promoting soft agar growth and invasion capability in lung cancer cells. Interestingly, the decrease in the expression of miR-29b by c-Myc is responsible for soft agar growth and invasiveness mediated by FHIT loss due to promoter methylation. Among patients, low expression of miR-29b and FHIT was more common in tumors with high c-Myc expression than in tumors with low c-Myc expression. Kaplan-Meier and Cox regression analysis showed that tumors with high c-Myc, low miR-29b and low FHIT expression had shorter OS and RFS periods than their counterparts. In conclusion, the decrease in the expression of miR-29b by c-Myc may be responsible for FHIT loss-mediated tumor aggressiveness and for poor outcome in NSCLC. Therefore, we suggest that restoration of the miR-29b expression using the c-Myc inhibitor might be helpful in suppressing tumor aggressiveness mediated by FHIT loss and consequently improving outcomes in NSCLC patients with tumors with low expression of FHIT.

UR - http://www.scopus.com/inward/record.url?scp=84938934841&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938934841&partnerID=8YFLogxK

U2 - 10.1038/onc.2014.152

DO - 10.1038/onc.2014.152

M3 - Article

C2 - 24909176

AN - SCOPUS:84938934841

VL - 34

SP - 2072

EP - 2082

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 16

ER -